Due to the poor efficacy and high toxicity of STAT inhibitors in early pre-clinical trials, much research has focused on targeting upstream pathways to reduce phosphorylation and/or activation of STAT3 in tumour cells. This evidence concerns the gene STAT3 and neoplasm.